This book provides an authoritative overview of botulinum neurotoxin (BoNT) treatment menus for 16 pain categories with an evidence-based literature review on each pain disorder, illustrative figures showing anatomy and techniques Introductory chapters cover basic information about the mechanism, function and the analgesic effects of the BoNTs based on the data derived from animal studies. Clinical chapters define pain in conditions such as post-herpetic and post-traumatic neuralgias, plantar fasciitis, low back pain, post-surgical pain syndromes and migraine in detail, provide discussion of current modes of treatment and updated information on BoNT therapy. Each chapter also includes illustrative case histories. The new edition is updated with all the new findings since the explosion in research and literature since 2015. New chapters on the history and pain in dentistry round out the update. Botulinum Toxin Treatment of Pain Disorders provides an invaluable resource for clinicians and researchers involved in the treatment of pain disorders including neurologists, pain medicine specialists, anesthesiologists, internists, those conducting research in pharmacology and toxicology as well as students in these areas.

This second edition offers 88 chapters divided among three volumes providing the most comprehensive source of know-how in the wide-ranging field of Mitochondrial Medicine. Volume III guides readers through chapters on intercellular mitochondrial transfer, Cytoplasmic transfer methods, Ndufs4 knockout mouse, in vivo assessment of mitochondrial oxygen consumption, mitochondrial network analysis by imaging, mitochondrial respiration in platelets, Heterologous Inferential Analysis (HIA), bioenergetic profiling, integrative methods for studying cardiac energetics, and isolation and deep sequencing of mitochondrial DNA.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, application details for both the expert and non-expert reader, and tips on troubleshooting and avoiding known pitfalls. Authoritative and accessible, Mitochondrial Medicine, Second Edition, Volume 3: Manipulating Mitochondria and Disease- Specific Approaches aims to be a comprehensive source of know-how in the wide-ranging field of Mitochondrial Medicine.

Microbial physiology, biochemistry and genetics allowed the formulation of concepts that turned out to be important in the study of higher organisms. In the first section, the principles of bacterial growth are given, as well as the description of the different layers that enclose the bacterial cytoplasm, and their role in obtaining nutrients from the outside media through different permeability mechanism described in detail. A chapter is devoted to allostery and is indispensable for the comprehension of many regulatory mechanisms described throughout the book. Another section analyses the mechanisms by which cells obtain the energy necessary for their growth, glycolysis, the pentose phosphate pathway, the tricarboxylic and the anaplerotic cycles. Two chapters are devoted to classes of microorganisms rarely dealt with in textbooks, namely the Archaea, mainly the methanogenic bacteria, and the methylotrophs. Eight chapters describe the principles of the regulations at the transcriptional level, with the necessary knowledge of the machineries of transcription and translation. The next fifteen chapters deal with the biosynthesis of the cell building blocks, amino acids, purine and pyrimidine nucleotides and deoxynucleotides, water-soluble vitamins and coenzymes, isoprene and tetrapyrrole derivatives and vitamin B12. The two last chapters are devoted to the study of protein-DNA interactions and to the evolution of biosynthetic pathways. The considerable advances made in the last thirty years in the field by the introduction of gene cloning and sequencing and by the exponential development of physical methods such as X-ray crystallography or nuclear magnetic resonance have helped presenting metabolism under a multidisciplinary attractive angle.

Therapeutic risk management of medicines is an authoritative and practical guide on developing, implementing and evaluating risk management plans for medicines globally. It explains how to assess risks and benefit-risk balance, design and roll out risk minimisation and pharmacovigilance activities, and interact effectively with key stakeholders.

A more systematic approach for managing the risks of medicines arose following a number of high-profile drug safety incidents and a need for better access to effective but potentially risky treatments. Regulatory requirements have evolved rapidly over the past decade. Risk management plans (RMPs) are mandatory for new medicinal products in the EU and a Risk Evaluation and Mitigation Strategy (REMS) is needed for certain drugs in the US.

This book is an easy-to-read resource that complements current regulatory guidance, by exploring key areas and practical implications in greater detail. It is structured into chapters encompassing a background to therapeutic risk management, strategies for developing RMPs, implementation of RMPs, and the continuing evolution of the risk management field.The topic is of critical importance not only to the pharmaceutical and biotechnology industries, but also regulators and healthcare policymakers.Some chapters feature contributions from selected industry experts.
An up-to-date practical guide on conceiving, designing, and implementing global therapeutic risk management plans for medicinesA number of useful frameworks are presented which add impact to RMPs (Risk Management Plans), together with regional specific information (European Union, United States, and Japan)Acomprehensive guide for performing risk management more effectively throughout a product s life-cycle"

The difficulty in achieving effective translation of basic mechanistic biomedical knowledge into effective therapeutics, is the greatest challenge in biomedical research. Nowhere is this more apparent than in the reductionist approaches to understanding and manipulating the acute inflammatory response in the settings of sepsis, trauma/hemorrhage, wound healing, and related processes. This book discusses complex systems and computational biology methods and approaches that have advanced sufficiently to allow for knowledge generation, knowledge integration, and clinical translation in the settings of complex diseases related to the inflammatory response. Well-regulated, self-resolving inflammation is necessary for the appropriate communication and resolution of infection and trauma, and for maintenance of proper physiology and homeostasis. In contrast, self-sustaining inflammation drives the pathobiology of the aforementioned diseases. It is now increasingly recognized that controlling and reprogramming inflammation in order to reap the benefits of this evolutionarily-conserved process is preferred to simply abolishing indiscriminately.

"Systems Biology of Apoptosis" summarizes all current achievements in this emerging field. Apoptosis is a process common to all multicellular organisms. Apoptosis leads to the elimination of cells via a complex but highly defined cellular programme. Defects in the regulation of apoptosis result in serious diseases such as cancer, autoimmunity, AIDS and neurodegeneration. Recently, a substantial step forward in understanding the complex apoptotic pathways has been made by utilising systems biology approaches. Systems biology combines rigorous mathematical modelling with experimental approaches in a closed loop cycle for advancing our knowledge about complex biological processes. In this book, the editor describes the contemporary systems biology studies devoted to apoptotic signaling and focuses on the question how systems biology helps to understand life/death decisions made in the cell and to develop new approaches to rational treatment strategies.

The annual cost of medical care in the U niled States is rapidly approaching a trillion dollars. Without doubt, much of the rise in costs is due to our health industry's concentration on high technology remediation and risk avoidance measures. From recent public discussions it is becoming in creasingly evident that to contain the costs and at the same time extend the benefits of health care without national bankruptcy will necessitate much greater attention to preventative medicine. The total cost of waste disposal by our health industry is well over a billion dollars. It is rising rapidly as we increasingly rely on high technol ogy remediation measures. Here, too, in the opinion of the authors of this work, it would be prudent to give much greater attention to preventative approaches. Incineration technology has largely been developed for disposing mu nicipal solid waste (MSW) and hazardous waste (HW). As a result of the multibillion dollar funding for the Resource Conservation and Recovery Act (RCRA), most experts believe that pollution control is the key to minimizing toxic emissions from incinerators. This view is now beginning to take hold in medical waste (MW) incineration as well. However, the authors contributing to this book have concluded that precombustion measures can be most effective in reducing the toxic products of medical waste incineration."

Nations around the world are experiencing a spectacular increase in longevity. Society as a whole is being challenged by issues arising from this revolution in longevity. Although the specter of the loneliness and existential suffering of older citizens is such that some people under the age of 65 find it difficult to conceive of a long-term future, persons over 85 have proven that aging does not necessarily preclude a healthy and productive life. Extraordinary progress in both curative and preventive medicine justifies optimism about the quality of life and state of well-being that can be enjoyed even in great old age. We should look to professionals in diverse fields to develop creative solutions to the inevitable issues that will arise with aging. Governments must prepare for the future health of their citizens by making long-term investments to educate all sectors of society in the value of good nutrition, exercise, and lifestyles that enhance well-being throughout life. Also, governments should realize that the main cause of health care expenditure is serious illness which occurs in persons of all ages, and not predominantly in older people. Early detection can help save lives, as well. Health and longevity of life will ultimately end as a political issue. What is needed is long-term government investments necessary for a viable health policy. The question arises: will world leaders be able to commit to such a policy? Two major socioeconomic phenomena may have a regulating effect on this issue. The first is the emergence of pressure groups that have come into being in response to a particular health issue, such as AIDS. The second is the emergence of ethics committees in developed nations that deal solely with health issues.

This book presents novel and advanced topics in Medical Image Processing and Computational Vision in order to solidify knowledge in the related fields and define their key stakeholders. It contains extended versions of selected papers presented in VipIMAGE 2013 - IV International ECCOMAS Thematic Conference on Computational Vision and Medical Image, which took place in Funchal, Madeira, Portugal, 14-16 October 2013. The twenty-two chapters were written by invited experts of international recognition and address important issues in medical image processing and computational vision, including: 3D vision, 3D visualization, colour quantisation, continuum mechanics, data fusion, data mining, face recognition, GPU parallelisation, image acquisition and reconstruction, image and video analysis, image clustering, image registration, image restoring, image segmentation, machine learning, modelling and simulation, object detection, object recognition, object tracking, optical flow, pattern recognition, pose estimation, and texture analysis. Different applications are addressed and described throughout the book, comprising: biomechanical studies, bio-structure modelling and simulation, bone characterization, cell tracking, computer-aided diagnosis, dental imaging, face recognition, hand gestures detection and recognition, human motion analysis, human-computer interaction, image and video understanding, image processing, image segmentation, object and scene reconstruction, object recognition and tracking, remote robot control, and surgery planning. This volume is of use to researchers, students, practitioners and manufacturers from several multidisciplinary fields, such as artificial intelligence, bioengineering, biology, biomechanics, computational mechanics, computational vision, computer graphics, computer science, computer vision, human motion, imagiology, machine learning, machine vision, mathematics, medical image, medicine, pattern recognition, and physics.

"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings's College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.

Counterfeit drugs continue to infiltrate the drug market in the United States, causing illness and death. This book addresses this issue and examines the recent trends in drug counterfeiting over the past 5-10 years. The text shows perspectives from crime lab and toxicology lab personnel and academic researchers, and includes topics such as a history of cases and issues with counterfeit drugs, trends observed in forensic labs, instrumental methods and approaches used in detecting counterfeit medicines, and policy approaches for controlling counterfeit drugs. There is a focus on ways to reduce counterfeit drugs in the market, to help improve the health and safety of people all over the world. Features : Focuses on recent (5-10) year trends in counterfeit drugs and analysis. Shows perspectives from crime lab and toxicology lab personnel and academic researchers. Focuses on drugs seized by law enforcement and approaches to reducing counterfeit medicine in the market. Discusses the detection and analysis of counterfeit drugs, and appropriate tools for combating this issue. Emphasizes the global impact of illegal medicines.

This book begins with an introduction of pragmatic cluster randomized trials (PCTs) and reviews various pragmatic issues that need to be addressed by statisticians at the design stage. It discusses the advantages and disadvantages of each type of PCT, and provides sample size formulas, sensitivity analyses, and examples for sample size calculation. The generalized estimating equation (GEE) method will be employed to derive sample size formulas for various types of outcomes from the exponential family, including continuous, binary, and count variables. Experimental designs that have been frequently employed in PCTs will be discussed, including cluster randomized designs, matched-pair cluster randomized design, stratified cluster randomized design, stepped-wedge cluster randomized design, longitudinal cluster randomized design, and crossover cluster randomized design. It demonstrates that the GEE approach is flexible to accommodate pragmatic issues such as hierarchical correlation structures, different missing data patterns, randomly varying cluster sizes, etc. It has been reported that the GEE approach leads to under-estimated variance with limited numbers of clusters. The remedy for this limitation is investigated for the design of PCTs. This book can assist practitioners in the design of PCTs by providing a description of the advantages and disadvantages of various PCTs and sample size formulas that address various pragmatic issues, facilitating the proper implementation of PCTs to improve health care. It can also serve as a textbook for biostatistics students at the graduate level to enhance their knowledge or skill in clinical trial design. Key Features: Discuss the advantages and disadvantages of each type of PCTs, and provide sample size formulas, sensitivity analyses, and examples. Address an unmet need for guidance books on sample size calculations for PCTs; A wide variety of experimental designs adopted by PCTs are covered; The sample size solutions can be readily implemented due to the accommodation of common pragmatic issues encountered in real-world practice; Useful to both academic and industrial biostatisticians involved in clinical trial design; Can be used as a textbook for graduate students majoring in statistics and biostatistics.

Johannes Klumpers Biotechnologies, such as genetic engineering, cloning and biodiversity, raise many legal and ethical concerns, so it is important that people understand these issues and feel able to express their opinions. This is why the European Commission has been, for a number of years, supporting actions to improve communication among scientists in these diverse areas. The project 'Women in Biotechnology' (WONBIT), financed under the 6th Framework programme of the European Commission, is an excellent example of what can be done to target opinion-formers such as scientists, economists and lawyers in bottom-up activities, and to encourage a debate on gender issues triggered by developments in the life sciences. WONBIT gave rise to a successful international conference highlighting the importance of adopting good practices and ethical considerations in parallel with the rapid pace of progress in biotechnology - from a woman's point of view. In particular, the conference addressed women in decision-making positions in b- technology with specific reference to scientific excellence, social competencies and management qualities as well as issues relating to environment, society and the younger generation. But it did not stop there: a key part of the conference was dedicated to stimulating public debate among non-specialists, which has led to a number of recommen- tions to policy-makers on better communication in biotechnology, on taking better account of the gender aspects of research, and on involving more women in the decision-making process that surrounds developments in biotechnology.

Stem cell therapy is ushering in a new era of medicine in which we will be able to repair human organs and tissue at their most fundamental level- that of the cell. The power of stem cells to regenerate cells of specific types, such as heart, liver, and muscle, is unique and extraordinary. In 1998 researchers learned how to isolate and culture embryonic stem cells, which are only obtainable through the destruction of human embryos. An ethical debate has raged since then about the ethics of this research, usually pitting pro-life advocates vs. those who see the great promise of curing some of humanity's most persistent diseases.
In this book Cynthia Cohen agrees that we need to work toward a consensus on the issue of how we treat the embryo. But more broadly she claims that we need to transform and expand the ethical and policy debates on stem cells (adult and embryonic). This important and much-needed book is both a primer and a means by which to understand the implications of this research. Cohen starts by introducing readers to the basic science of stem cell research, and the core ethical questions surrounding the embryo. She then expands the scope of the debate, looking at the moral questions that will crop up down the line, such as e.g. the use of therapeutic cloning to overcome the body's immune resistance to stem cells; the ethics of using animals to test stem cells; how to disentangle federal and state legal and regulatory policies in pursuit of a coherent national policy; and how to develop an ethics of stem cell research that will accommodate new techniques and controversies that we cannot even foresee now. Her final chapter develops a concrete plan for an oversight systemfor this research.
This is the first single-author book that addresses the many broad ethical and legal issues related to stem cells, and it should be of great interest to bioethicists, researchers, clinicians, philosophers, theologians, lawyers, policy makers, and general readers.

'I am blown away by the level of detail Phil Cavell brings to his work.' - Elinor Barker MBE, multiple world champion and Olympic gold medallist 'The Midlife Cyclist is a triumph' - Cycling Plus 'An amazing accomplishment... a simple-to-understand precis of your midlife as a cyclist - you won't want to put it down.' - Phil Liggett, TV cycling commentator 'Phil is eminently qualified to write The Midlife Cyclist. Well, he is certainly old enough.' - Fabian Cancellara, Tour de France rider and two-time Olympic champion Renowned cycling biomechanics pioneer, Phil Cavell, explores the growing trend of middle-aged and older cyclists seeking to achieve high-level performance. Using contributions from leading coaches, ex-professionals and pro-team doctors, he produces the ultimate manifesto for mature riders who want to stay healthy, avoid injury - and maximise their achievement levels. Time's arrow traditionally plots an incremental path into declining strength and speed for all of us. But we are different to every other generation of cyclists in human history. An ever-growing number of us are determined to scale the highest peaks of elite physical fitness into middle-age and beyond. Can the emerging medical and scientific research help us achieve the holy triumvirate of speed and health with age? The Midlife Cyclist offers a gold standard road-map for the mature cyclist who aims to train, perform and even race at the highest possible level.

This book provides the first comprehensive overview of the emerging field of interdisciplinary salivary bioscience. It serves as a foundational reference guide to the collection, analysis, and interpretation of salivary data, as well as its myriad applications in medicine, surveillance and public health. The ease and non-invasive nature of saliva collection makes it highly useful in diverse fields such as pediatrics, dentistry, neuroscience, psychology, animal welfare and precision medicine. This book introduces students and scientists alike to the vast potential of salivary bioscience in both research and practice.

This book, which is the first volume of Biomedical Translational Research, summarizes emerging technologies in healthcare. The book reviews the advancements in biomedical sciences in genomics, immunology, stem cell, tissue engineering, nanotechnology, computational and structural biology, biomedical engineering, and telemedicine biology. The book highlights the applications of artificial intelligence in the diagnosis of infectious diseases and examines the role of system biology approaches for understanding human complexity, variability, and its influence on health and diseases. It presents the applications of flow cytometry in monitoring the progression and treatment of disease. It covers emerging technologies in cancer research, including CRISPR-Cas9, NGS, and nanotechnology. This book is a useful source of information for clinical researchers, basic scientists, biomedical engineers, and computational biologists.

New discoveries in the field of stem cells increasingly dominate the news and scientific literature revealing an avalanche of new knowledge and research tools that are producing therapies for cancer, heart disease, diabetes, and a wide variety of other diseases that afflict humanity. The Handbook of Stem Cells integrates this exciting area of life science, combining in two volumes the requisites for a general understanding of adult and embryonic stem cells. Organized in two volumes entitled Pluripotent Stem Cells & Cell Biology and Adult & Fetal Stem Cells, this work contains contributions from the world s experts in stem cell research to provide a description of the tools, methods, and experimental protocols needed to study and characterize stem cells and progenitor populations as well as a the latest information of what is known about each specific organ system.
* Provides comprehensive coverage on this highly topical subject
* Contains contributions by the foremost authorities and premiere names in the field of stem cell research
*Companion website - http: //booksite.elsevier.com/9780123859426/- containsover 250 color figures in presentation format"

Much research has focused on the basic cellular and molecular biological aspects of stem cells. Much of this research has been fueled by their potential for use in regenerative medicine applications, which has in turn spurred growing numbers of translational and clinical studies. However, more work is needed if the potential is to be realized for improvement of the lives and well-being of patients with numerous diseases and conditions.This book series 'Cell Biology and Translational Medicine (CBTMED)' as part of SpringerNature's longstanding and very successful Advances in Experimental Medicine and Biology book series, has the goal to accelerate advances by timely information exchange. Emerging areas of regenerative medicine and translational aspects of stem cells are covered in each volume. Outstanding researchers are recruited to highlight developments and remaining challenges in both the basic research and clinical arenas. This current book is the thirteenth volume of a continuing series.

Eleven essays by historians and sociologists examine cancer research and treatment as everyday practice in post-war Europe and North America. These are not stories of inevitable medical progress and obstacles overcome, but of historical contingencies, cultural differences, hope, and often disappointed expectations.

This second edition offers 88 chapters divided among three volumes providing the most comprehensive source of know-how in the wide-ranging field of Mitochondrial Medicine. Volume I guides readers through chapters on QSAR models, DQAsomes, synthesis of Triphenylphosphonium Phospholipid Conjugates, testing of novel isomeric mitochondriotropic derivatives, mTRIP, mitochondria-targeted imaging nanoplatforms, live-cell assessment, mitochondrial coenzyme Q10, rat liver Mitochondrial Lipidome, and Mito-SinCe2. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, application details for both the expert and non-expert reader, and tips on troubleshooting and avoiding known pitfalls. Authoritative and accessible, Mitochondrial Medicine, Second Edition, Volume 1: Targeting Mitochondria aims to be a comprehensive source of know-how in the wide-ranging field of Mitochondrial Medicine.

This book discusses properties of apoptosis and other cell death modalities in cancer pathogenesis and treatment. Its nine chapters discuss modulation of anti-tumor inflammatory and immune responses, effects on the tumor microenvironment, to strategies for improving pro-apoptotic therapies, mechanisms and implications for disease pathogenesis, axl and mer receptor tyrosine kinases, immunogenic apoptotic cell death and anti-cancer immunity and cancer cell death-inducing radiotherapy. This book places the onco-biology of apoptosis in clear and objective perspective through an expertly synthesized series of reviews. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy is a deft and thorough exploration of cutting-edge research in apoptosis and anti-cancer mechanisms from basic biology to oncology. It highlights a rapidly growing field within cancer research and is essential reading for oncologists, biochemists and advanced graduate students alike.

Global security threats have created a complex risk landscape that is challenging and transforming society. These global security issues intersect and influence the political, economic, social, technological, ecological and legal dimensions of the complex risk landscape and are now transborder thereby becoming national security issues. Accessing the innovation space to support safety, security and defence capabilities is critical in order to mitigate new and evolving threats. Through real-world examples of innovation, this book provides a detailed examination of the innovation space as it pertains to the application of S&T to safety and security threats and challenges. This book is of most interest to public and private sector innovators as well as academician and graduate students working in the safety and security domain.